Imugene Limited (IUGNF)
| Market Cap | 24.07M -51.8% |
| Revenue (ttm) | 2.63M -11.5% |
| Net Income | -39.02M |
| EPS | -0.15 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.0700 |
| Previous Close | 0.0700 |
| Day's Range | 0.0650 - 0.0700 |
| 52-Week Range | 0.0550 - 0.3101 |
| Beta | 2.09 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 25, 2026 |
About Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tum... [Read more]
Financial Performance
In fiscal year 2025, Imugene's revenue was 4.40 million, a decrease of -11.53% compared to the previous year's 4.97 million. Losses were -69.02 million, -53.89% less than in 2024.
Financial numbers in AUD Financial StatementsNews
Imugene Slides: Study update presentation
Imugene has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
New York, May 20, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an update note on Imugene Ltd. (ASX: IMU)...
Imugene Earnings release: Q3 2026
Imugene released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
Imugene Quarterly report: H1 2026
Imugene has published its H1 2026 quarterly earnings report on February 24, 2026.
Imugene Earnings release: Q2 2026
Imugene released its Q2 2026 earnings on January 29, 2026, summarizing the period's financial results.
Imugene Transcript: FDA Meeting Update
FDA guidance enables direct progression to phase III for azer-cel, reducing regulatory risk and streamlining approval. Strong clinical data and validated manufacturing support commercial readiness, with multiple partnership and funding options under consideration.
Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours
Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR...
Imugene Transcript: Collaboration
A strategic partnership will combine an oncolytic virus platform with JW's approved CD19 CAR-T therapy to target solid tumors, starting with preclinical work and aiming for a phase one trial in China as early as 2026. Imugene retains full IP ownership and both parties emphasize capital efficiency and rapid development.
Imugene Press release: Collaboration
Imugene issued a press release on November 26, 2025, disclosing material business information to investors.
Imugene Slides: FY 2025
Imugene has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 12, 2025.
Imugene Transcript: Investor Update
Azer-cel shows strong efficacy and durability in both relapsed and CAR T naive lymphoma patients, with a favorable safety profile and FDA Fast Track status. Strategic focus shifts to partnerships and pivotal studies, with key updates expected after FDA meetings and at the ASH conference.
Imugene Earnings release: Q1 2026
Imugene released its Q1 2026 earnings on October 30, 2025, summarizing the period's financial results.
Imugene Annual report: H2 2025
Imugene has published its H2 2025 annual report on August 26, 2025.
Imugene Transcript: EGM 2025
Three resolutions on share placements and options were overwhelmingly approved, with over 91% support each. Strategic focus remains on advancing the allogeneic CAR-T program, cost reduction, and upcoming pivotal studies, with no shareholder questions raised.
Imugene Slides: FY 2025
Imugene has posted slides in relation to its FY 2025 quarterly earnings report, which was published on August 19, 2025.
Imugene Earnings release: Q4 2025
Imugene released its Q4 2025 earnings on July 30, 2025, summarizing the period's financial results.
Imugene Announces Outstanding Response Rates from the Phase 1b Trial of the Azer-cel Allogeneic CAR T in 3L+ DLBCL
Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and 3 PR in Phase 1...
Imugene Transcript: EGM 2025
The meeting approved share consolidation and new share issuance, with strong majorities for both. Management highlighted clinical progress, cost-cutting, and strategic plans, while addressing shareholder concerns about share price and data updates.
Imugene Slides: FY 2025
Imugene has posted slides in relation to its FY 2025 quarterly earnings report, which was published on June 25, 2025.
Imugene Earnings release: Q3 2025
Imugene released its Q3 2025 earnings on April 29, 2025, summarizing the period's financial results.
Imugene Transcript: Investor Update
Management addressed share price decline, citing lack of licensing deals, slow data, and high cash burn, but highlighted strong clinical progress with azer-cel, OnCARlytics, and VAXINIA. Cost controls have reduced headcount, and business development focuses on partnerships and out-licensing.
Imugene Transcript: NWR Virtual Healthcare Conference
The event showcased advances in allogeneic CAR T and oncolytic virus therapies, with promising clinical results and FDA Fast Track status. Strategic focus is on registrational studies, partnerships, and expanding patient recruitment, with key data readouts expected in the next year.
Imugene Quarterly report: H1 2025
Imugene has published its H1 2025 quarterly earnings report on February 27, 2025.
Imugene Earnings release: Q2 2025
Imugene released its Q2 2025 earnings on January 29, 2025, summarizing the period's financial results.
Imugene Transcript: AGM 2024
The meeting covered board changes, voting on key resolutions, and updates on clinical programs in CAR T and oncolytic viruses. Strategic plans include advancing trials, pursuing regulatory milestones, and exploring commercialization options. VAXINIA received orphan drug status.